United Drug Patent Portfolio
United owns 4 orange book drugs protected by 35 US patents Given below is the list of United's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11826327 | Treatment for interstitial lung disease | 03 Feb, 2042 | Active |
| US10421729 | Microcrystalline diketopiperazine compositions and methods | 01 Apr, 2035 | Active |
| US12679811 | Microcrystalline Diketopiperazine Compositions And Methods | 14 Mar, 2034 | Active |
| US8747897 | Osmotic drug delivery system | 11 Aug, 2031 | Active |
| US8349892 | Solid formulations of prostacyclin analogs | 22 Jan, 2031 | Active |
| US10772883 | Diketopiperazine microparticles with defined specific surface areas | 11 Jun, 2030 | Active |
| US8410169 | Compounds and methods for delivery of prostacyclin analogs | 13 Feb, 2030 | Active |
| US7999007 | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same | 29 Mar, 2029 | Active |
| US11723887 | Process to prepare treprostinil, the active ingredient in Remodulin® | 15 Dec, 2028 | Active |
| US8497393 | Process to prepare treprostinil, the active ingredient in Remodulin® | 15 Dec, 2028 | Active |
| US9593066 | Process to prepare treprostinil, the active ingredient in remodulin® | 15 Dec, 2028 | Active |
| US9604901 | Process to prepare treprostinil, the active ingredient in Remodulin® | 15 Dec, 2028 | Active |
| US8653137 | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same | 05 Sep, 2028 | Active |
| US8658694 | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same | 05 Sep, 2028 | Active |
| US9358240 | Treprostinil administration by inhalation | 05 May, 2028 | Active |
| US9339507 | Treprostinil administration by inhalation | 10 Mar, 2028 | Active |
| US10376525 | Treprostinil administration by inhalation | 14 May, 2027 | Active |
| US10716793 | Treprostinil administration by inhalation | 14 May, 2027 | Active |
| US11357782 | Treprostinil administration by inhalation | 14 May, 2027 | Active |
| US7417070 | Compounds and methods for delivery of prostacyclin analogs | 30 Jul, 2026 | Expired |
| US9393203 | Osmotic drug delivery system | 27 Apr, 2026 | Expired |
| US10130685 | Diketopiperazine salts for drug delivery and related methods | 23 Aug, 2025 | Expired |
| US10076505 | Inhalation formulations of Treprostinil | 16 Dec, 2024 | Expired |
| US10695308 | Inhalation formulations of treprostinil | 16 Dec, 2024 | Expired |
| US9713599 | Parenteral formulations of treprostinil | 16 Dec, 2024 | Expired |
| US7544713 | Compounds and methods for delivery of prostacyclin analogs | 14 Jul, 2024 | Expired |
| US8252839 | Compounds and methods for delivery of prostacyclin analogs | 24 May, 2024 | Expired |
| US9050311 | Compounds and methods for delivery of prostacyclin analogs | 24 May, 2024 | Expired |
| US9278901 | Compounds and methods for delivery of prostacyclin analogs | 24 May, 2024 | Expired |
| US9422223 | Compounds and methods for delivery of prostacyclin analogs | 24 May, 2024 | Expired |
| US9199908 | Compounds and methods for delivery of prostacyclin analogs | 24 May, 2024 | Expired |
| US6521212 | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation | 13 Nov, 2018 | Expired |
| US6756033 | Method for delivering benzindene prostaglandins by inhalation | 13 Nov, 2018 | Expired |
| US6765117 | Process for stereoselective synthesis of prostacyclin derivatives | 24 Oct, 2017 | Expired |
| US5153222 | Method of treating pulmonary hypertension with benzidine prostaglandins | 16 Oct, 2014 | Expired |
Latest Legal Activities on United's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of United.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Nov, 2025 | US8747897 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Nov, 2025 | US11357782 (Litigated) |
| Expire Patent | 01 Sep, 2025 | US9713599 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Aug, 2025 | US8658694 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Aug, 2025 | US8653137 (Litigated) |
| Recordation of Patent eCertificate of Correction | 08 Jul, 2025 | US11826327 |
| Patent eCofC Notification | 08 Jul, 2025 | US11826327 |
| Mail Patent eCofC Notification | 08 Jul, 2025 | US11826327 |
| Patent eCofC Notification | 08 Jul, 2025 | US11826327 |
| Email Notification | 08 Jul, 2025 | US11826327 |
| Email Notification | 08 Jul, 2025 | US11826327 |
| Mail Patent eCofC Notification | 08 Jul, 2025 | US11826327 |
| Recordation of Patent eCertificate of Correction | 08 Jul, 2025 | US11826327 |
| Expire Patent | 05 May, 2025 | US8410169 (Litigated) |
| Maintenance Fee Reminder Mailed | 17 Mar, 2025 | US9713599 |
United's Drug Patent Litigations
United's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 02, 2015, against patent number US8497393. The petitioner SteadyMed Ltd. et al., challenged the validity of this patent, with United Therapeutics Corporation as the respondent. Click below to track the latest information on how companies are challenging United's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10716793 | January, 2021 |
Final Written Decision
(02 Feb, 2023)
| United Therapeutics Corporation | Liquidia Technologies, Inc. |
| US9604901 | March, 2020 |
Final Written Decision
(08 Oct, 2021)
| United Therapeutics Corp. | Liquidia Technolgies, Inc. |
| US9593066 | March, 2020 |
Institution Denied
(13 Oct, 2020)
| United Therapeutics Corp. | Liquidia Technologies, Inc. |
| US9339507 | June, 2017 |
Terminated-Settled
(27 Aug, 2018)
| United Therapeutics Corp. | Watson Laboratories, Inc. |
| US9358240 | June, 2017 |
Terminated-Settled
(27 Aug, 2018)
| United Therapeutics Corp. | Watson Laboratories, Inc. |
| US8497393 | October, 2015 |
Final Written Decision
(31 Mar, 2017)
| United Therapeutics Corporation | SteadyMed Ltd. et al. |
United Drug Patents' Oppositions Filed in EPO
United drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 08, 2012, by Sandoz Ag. This opposition was filed on patent number EP07755989A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP13188882A | Dec, 2019 | Generics [UK] Ltd | Revoked |
| EP13188882A | Nov, 2019 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP04776104A | Oct, 2017 | Teva Pharmaceutical Industries Ltd | Patent maintained as amended |
| EP08829225A | Oct, 2016 | Generics (U.K.) Limited | Revoked |
| EP08829225A | Sep, 2016 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP07755989A | Aug, 2012 | Sandoz AG | Revoked |
United's Family Patents
United drugs have patent protection in a total of 22 countries. It's US patent count contributes only to 39.2% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Clinical Trials
Recent Clinical Trials by United:
United Drug List
Given below is the complete list of United's drugs and the patents protecting them.
1. Orenitram
Orenitram is protected by 16 patents, out of which 9 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8747897 | Osmotic drug delivery system |
11 Aug, 2031
(4 years from now)
| Active |
| US8349892 | Solid formulations of prostacyclin analogs |
22 Jan, 2031
(4 years from now)
| Active |
| US8410169 | Compounds and methods for delivery of prostacyclin analogs |
13 Feb, 2030
(3 years from now)
| Active |
| US11723887 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(2 years from now)
| Active |
| US8497393 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(2 years from now)
| Active |
| US9593066 | Process to prepare treprostinil, the active ingredient in remodulin® |
15 Dec, 2028
(2 years from now)
| Active |
| US9604901 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(2 years from now)
| Active |
| US7417070 | Compounds and methods for delivery of prostacyclin analogs |
30 Jul, 2026
(2 months ago)
| Expired |
| US9393203 | Osmotic drug delivery system |
27 Apr, 2026
(5 months ago)
| Expired |
| US7544713 | Compounds and methods for delivery of prostacyclin analogs |
14 Jul, 2024
(2 years ago)
| Expired |
| US8252839 | Compounds and methods for delivery of prostacyclin analogs |
24 May, 2024
(2 years ago)
| Expired |
| US9050311 | Compounds and methods for delivery of prostacyclin analogs |
24 May, 2024
(2 years ago)
| Expired |
| US9278901 | Compounds and methods for delivery of prostacyclin analogs |
24 May, 2024
(2 years ago)
| Expired |
| US9422223 | Compounds and methods for delivery of prostacyclin analogs |
24 May, 2024
(2 years ago)
| Expired |
| US6765117 | Process for stereoselective synthesis of prostacyclin derivatives |
24 Oct, 2017
(8 years ago)
| Expired |
| US5153222 | Method of treating pulmonary hypertension with benzidine prostaglandins |
16 Oct, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orenitram's drug page
2. Remodulin
Remodulin is protected by 13 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7999007 | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
29 Mar, 2029
(2 years from now)
| Active |
| US11723887 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(2 years from now)
| Active |
| US8497393 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(2 years from now)
| Active |
| US9593066 | Process to prepare treprostinil, the active ingredient in remodulin® |
15 Dec, 2028
(2 years from now)
| Active |
| US9604901 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(2 years from now)
| Active |
| US8653137 | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
05 Sep, 2028
(1 year, 11 months from now)
| Active |
| US8658694 | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
05 Sep, 2028
(1 year, 11 months from now)
| Active |
| US10076505 | Inhalation formulations of Treprostinil |
16 Dec, 2024
(1 year, 9 months ago)
| Expired |
| US10695308 | Inhalation formulations of treprostinil |
16 Dec, 2024
(1 year, 9 months ago)
| Expired |
| US9713599 | Parenteral formulations of treprostinil |
16 Dec, 2024
(1 year, 9 months ago)
| Expired |
| US9199908 | Compounds and methods for delivery of prostacyclin analogs |
24 May, 2024
(2 years ago)
| Expired |
| US6765117 | Process for stereoselective synthesis of prostacyclin derivatives |
24 Oct, 2017
(8 years ago)
| Expired |
| US5153222 | Method of treating pulmonary hypertension with benzidine prostaglandins |
06 Oct, 2014
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Remodulin's drug page
3. Tyvaso
Tyvaso is protected by 13 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11826327 | Treatment for interstitial lung disease |
03 Feb, 2042
(15 years from now)
| Active |
| US11723887 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(2 years from now)
| Active |
| US8497393 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(2 years from now)
| Active |
| US9593066 | Process to prepare treprostinil, the active ingredient in remodulin® |
15 Dec, 2028
(2 years from now)
| Active |
| US9604901 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(2 years from now)
| Active |
| US9358240 | Treprostinil administration by inhalation |
05 May, 2028
(1 year, 6 months from now)
| Active |
| US9339507 | Treprostinil administration by inhalation |
10 Mar, 2028
(1 year, 5 months from now)
| Active |
| US10376525 | Treprostinil administration by inhalation |
14 May, 2027
(7 months from now)
| Active |
| US10716793 | Treprostinil administration by inhalation |
14 May, 2027
(7 months from now)
| Active |
| US6521212 | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
13 Nov, 2018
(7 years ago)
| Expired |
| US6756033 | Method for delivering benzindene prostaglandins by inhalation |
13 Nov, 2018
(7 years ago)
| Expired |
| US6765117 | Process for stereoselective synthesis of prostacyclin derivatives |
24 Oct, 2017
(8 years ago)
| Expired |
| US5153222 | Method of treating pulmonary hypertension with benzidine prostaglandins |
16 Oct, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tyvaso's drug page
4. Tyvaso Dpi
Tyvaso Dpi is protected by 10 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11826327 | Treatment for interstitial lung disease |
03 Feb, 2042
(15 years from now)
| Active |
| US10421729 | Microcrystalline diketopiperazine compositions and methods |
01 Apr, 2035
(8 years from now)
| Active |
| US12679811 | Microcrystalline Diketopiperazine Compositions And Methods |
14 Mar, 2034
(7 years from now)
| Active |
| US10772883 | Diketopiperazine microparticles with defined specific surface areas |
11 Jun, 2030
(3 years from now)
| Active |
| US11723887 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(2 years from now)
| Active |
| US9593066 | Process to prepare treprostinil, the active ingredient in remodulin® |
15 Dec, 2028
(2 years from now)
| Active |
| US9604901 | Process to prepare treprostinil, the active ingredient in Remodulin® |
15 Dec, 2028
(2 years from now)
| Active |
| US10716793 | Treprostinil administration by inhalation |
14 May, 2027
(7 months from now)
| Active |
| US11357782 | Treprostinil administration by inhalation |
14 May, 2027
(7 months from now)
| Active |
| US10130685 | Diketopiperazine salts for drug delivery and related methods |
23 Aug, 2025
(1 year, 1 month ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tyvaso Dpi's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List